HomeIndiaCovovax now accessible for youngsters matured 12-17 in India

Covovax now accessible for youngsters matured 12-17 in India

About Covovax

Adar Poonawalla, CEO of Serum Institute of India, launched Covovax, India’s first vaccine for the prevention of coronavirus (CoV), on Tuesday. The vaccine is now available for children across the country, Poonawalla said.

What is Covovax?

Covovax, a drug meant to prevent the coronavirus, is now available for children across India. Earlier this year, the drug was launched following the growing number of infections caused by the virus in the country and worldwide. Nearly half of all patients infected with the virus globally are from India.

Tests on over 3,000 Indian patients have been conducted successfully at leading hospitals, including AIIMS and Tata Memorial Hospital in Mumbai and many other smaller hospitals across India. The drug has been tested for its effectiveness in curing patients struck down with the virus and reducing mortality rates by up to 80%.

Is covovax available for children?

The drug will be available for children aged 12 years and above at a price of INR 800. Covovax is also available for pregnant women at a discounted price of INR 1,000. Its availability will give relief to parents of young children who are most vulnerable to contracting the coronavirus and allows them opportunities to travel abroad and return safely home to their loved ones.

Coronavirus is a common respiratory infection caused by a virus found in the gut and throat of humans and animals.und in the gut and throat of humans and animals. According to reports, this virus is responsible for one in every six deaths of children under the age of five in India.

Coronavirus infections are common among infants and young children, as well as among adults with weakened immune systems. These infections can also occur in older children and adults without underlying health problems, but they are usually milder.

“We are happy to announce that the DCGI has granted a license for use of Covovax in children between 12 and 17 years of age,” Samir Kulkarni, managing director of Serum Institute of India Limited said in the release. “We see this as another step forward toward ensuring high level of protection for people.” Follow for more news updates at hostspotnews.com/

Related Articles
temapil.in

Most Popular